Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kristin Jensen · 2026-07-01

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.

Source: BioPharma Dive